(Q33966340)

30 July 2017

title

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study (English)

1 reference

30 July 2017

0 references

Takahiko Nagamine

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

24 June 2010

1 reference

Neuropsychiatric Disease and Treatment

30 July 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

page(s)

281-288

1 reference

Pathogenesis and management of the dyslipidemia of the metabolic syndrome

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Glucose metabolism and catecholamines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Metabolic considerations in the use of antipsychotic medications: a review of recent evidence

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

The Expert Consensus Guideline Series. Treatment of behavioral emergencies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

The positive and negative syndrome scale (PANSS) for schizophrenia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Serum creatine kinase levels in chronic psychosis patients--a comparison between atypical and conventional antipsychotics.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2898166

Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20634880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

PMC publication ID

2898166

1 reference

30 July 2017

1 reference